Premium
Sleep quality and physical activity predict inflammatory responses in a human model of low dose endotoxin challenge
Author(s) -
Weiner Elizabeth Marie,
SkulasRay Ann C.,
Flock Michael,
Fleming Jennifer,
KrisEtherton Penny M.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.712.24
Subject(s) - sleep quality , medicine , sleep (system call) , physical activity , pharmacology , computer science , physical therapy , operating system , insomnia
Level of physical activity and poor sleep quality are associated with inflammation, chronic disease, and acute fatality. However, the links between lifestyle factors and the development of inflammation are incompletely understood. We examined whether levels of physical activity and sleep quality were predictive of acute inflammatory responses (peak CRP) in a human model of induced inflammation (IV 0.6 ng/kg endotoxin challenge). Volunteers were healthy adults (n = 18, ages 20–44 yrs, BMI 20–30 kg/m 2 ) who participated in a fish oil supplementation study. During the visit, subjects completed the Pittsburgh Sleep Quality Index, a visual analog scale of subjective sleep quality, and the International Physical Activity Questionnaire. Regression analyses identified subjective sleep quality during the past week as the best predictor of peak (24 h) CRP response (R 2 =57%, p=0.002). Adding baseline CRP improved model fit (R 2 =70%, p<0.001). Days of moderate physical activity predicted decreased peak CRP response in combination with sleep quality over the last month (R 2 =60%, p=0.004). Adding baseline CRP improved model fit (R 2 =67%, p=0.001). Our finding that poor sleep quality predicts an increased inflammatory response while moderate physical activity attenuates it has important implications for understanding the role of lifestyle factors in the development of inflammatory diseases. Support: USDA, CSREES, grant #2009–65200‐05973. ClinicalTrials.gov #: NCT01329965